Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ryotaro NakamuraCorey S Cutler

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to older patients. The relative benefits of HCT over non-HCT therapy in older patients with higher-risk MDS have not been defined. We conducted a multicenter biologic assignment trial comparing reduced-intensity HCT to hypomethylating therapy or best supportive care in subjects 50-75 years of age with intermediate-2 or high-risk de novo MDS. The primary outcome was overall survival probability at 3 years. Between January 2014 and November 2018, we enrolled 384 subjects at 34 centers. Subjects were assigned to the Donor or No-Donor arms according to the availability of a matched donor within 90 days of study registration. The median follow-up time for surviving subjects was 34.2 months (range: 2.3-38 months) in the Donor arm and 26.9 months (range: 2.4-37.2 months) in the No-Donor arm. In an intention-to-treat analysis, the adjusted overall survival rate at 3 years in the Donor arm was 47.9% (95% CI, 41.3 to 54.1) compared with 26.6% (95% CI, 18.4 to 35.6) in the No-Donor arm (P = .0001) with an absolute difference of 21.3% (95% CI, 10.2 to 31.8). Leukemia-free surv...Continue Reading

References

Apr 20, 2002·Lancet·Taane G ClarkBianca L De Stavola
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
Apr 13, 2004·International Journal of Epidemiology·Keith Wheatley, Richard Gray
Mar 10, 2007·Statistics in Medicine·John P KleinPer Kragh Andersen
Sep 14, 2007·Computer Methods and Programs in Biomedicine·Xu ZhangMei-Jie Zhang
Oct 30, 2008·Journal of the National Cancer Institute·Mikkael A SekeresJaroslaw P Maciejewski
Nov 26, 2008·Clinical Trials : Journal of the Society for Clinical Trials·Brent LoganNancy Geller
Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrea BacigalupoMary Horowitz
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettKeith Wheatley
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian L McCluneSergio Giralt
Jul 27, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas PrébetNorbert Vey
Aug 2, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Denise M OlianskyTheresa Hahn
May 15, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Uwe PlatzbeckerUNKNOWN Groupe Francophone des Myelodysplasies
Jun 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John KorethCorey Cutler
Aug 6, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rafael BejarBenjamin L Ebert
Sep 8, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matteo G Della PortaMario Cazzola
Feb 9, 2017·The New England Journal of Medicine·R Coleman LindsleyBenjamin L Ebert
Mar 16, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Aaron T GerdsWael Saber
Sep 18, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stefan O CiureaRichard E Champlin
Sep 3, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marie RobinNicolaus Kröger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.